## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off
Gastrointestinal stromal tumors: Current management
โ Scribed by Peter W.T. Pisters; Shreyaskumar R. Patel
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 150 KB
- Volume
- 102
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. Telomerase activity has been observed in 80 -90% of carcinomas derived from various organs. However, to the authors' knowledge this report is the first assessment of telomerase activity in gastrointestinal stromal tumors (GISTs). ## METHODS. Telomerase activity was analyzed by th
## Abstract Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm in the gastrointestinal tract and is associated with mutations of the __KIT__ or __PDGFRA__ gene. In addition, other genetic events are believed to be involved in GIST tumorigenesis. Cytogenetic aberrations as